Last $0.93 HKD
Change Today +0.02 / 2.20%
Volume 862.5K
1011 On Other Exchanges
Symbol
Exchange
Hong Kong
Berlin
As of 4:01 AM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

china nt pharma group co ltd (1011) Snapshot

Open
$0.94
Previous Close
$0.91
Day High
$0.94
Day Low
$0.90
52 Week High
02/13/14 - $1.54
52 Week Low
05/20/14 - $0.79
Market Cap
1.0B
Average Volume 10 Days
510.5K
EPS TTM
$-0.62
Shares Outstanding
1.1B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHINA NT PHARMA GROUP CO LTD (1011)

Related News

No related news articles were found.

china nt pharma group co ltd (1011) Related Businessweek News

No Related Businessweek News Found

china nt pharma group co ltd (1011) Details

China NT Pharma Group Company Limited, together with its subsidiaries, operates as a third-party pharmaceutical and vaccine promotion and sales services provider in China. It operates in three segments: Third-Party Pharmaceutical Promotion and Sales; Proprietary Products Production and Sales; and Third-Party Vaccines and Other Pharmaceuticals. The Third-Party Pharmaceutical Promotion and Sales segment engages in selling and marketing third-party manufactured pharmaceutical products to customers, as well as providing marketing and promotion services. The Proprietary Products Production and Sales segment is involved in the production and sale of branded products and generic drugs. The Third-Party Vaccines and Other Pharmaceuticals segment provides supply chain services for pharmaceutical/vaccine products. The company has approvals from the State Food and Drug Administration of China for 176 drug licenses to manufacture and sell pharmaceutical products. In addition, it offers consulting services. China NT Pharma Group Company Limited was founded in 1995 and is headquartered in Shanghai, the People's Republic of China.

640 Employees
Last Reported Date: 04/24/14
Founded in 1995

china nt pharma group co ltd (1011) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: CNY5.3M
Honorary Advisor
Total Annual Compensation: CNY2.0M
Compensation as of Fiscal Year 2013.

china nt pharma group co ltd (1011) Key Developments

China NT Pharma Group Company Limited Announces Approval of Application for Commencement of Phase II Clinical Trial for Myelodysplastic Syndromes

China NT Pharma Group Company Limited announced that the application for the commencement of the phase II clinical trial for myelodysplastic syndromes, a new indication for Xi Di Ke, a national class 1 new drug, has recently been approved by the Ethics Review Board of the Hematology Hospital of Chinese Academy of Medical Sciences. The group will commence the clinical trial at sixteen domestic clinical research centres shortly, which is expected to be completed by the end of 2016. MDS is a malignant myeloid clonal hemopathy characterized by decreased peripheral blood cells with ineffective myeloid production of various stages. Approximately one third of patients will develop acute myeloid leukemia after several months or years. At present it is globally considered as an incurable disease. The afore-mentioned clinical trial of Xi Di Ke is for the treatment of early and intermediate stages of MDS.

China NT Pharma Group Company Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2014

China NT Pharma Group Company Limited provided unaudited consolidated earnings guidance for the six months ended June 30, 2014. The Group is expected to record a net result around the breakeven region for the six months ended 30 June 2014, representing a substantial improvement of the results of the Group as compared to the net loss of approximately RMB 432 million for the corresponding period in 2013, mainly because no material restructuring cost is anticipated to be incurred for the six months ended 30 June 2014, as compared with total restructuring costs of approximately RMB 329 million for the corresponding period in 2013.

China NT Pharma Group Company Limited, Annual General Meeting, Jun 18, 2014

China NT Pharma Group Company Limited, Annual General Meeting, Jun 18, 2014., at 10:00 China Standard Time. Location: VIP Room V, 5/F. Agenda: To receive and adopt the audited consolidated financial statements of the company and the reports of the directors and auditors for the year ended 31 December 2013; to consider the re-election of the retiring directors of the company and authorise the board of directors to fix the remuneration of the directors of the company; to consider the re-appointment of Crowe Horwath (HK) CPA Limited as the auditors of the company and to authorise the board of directors of the company to fix their remuneration; and to allot, issue or otherwise deal with additional shares in the capital of the company or securities convertible into shares, or options, warrants or similar rights to subscribe for shares or such convertible securities of the company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
1011:HK $0.93 HKD +0.02

1011 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1011.
View Industry Companies
 

Industry Analysis

1011

Industry Average

Valuation 1011 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.0x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHINA NT PHARMA GROUP CO LTD, please visit www.ntpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.